New hope for liver cancer: triple therapy shows promise
NCT ID NCT05665348
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding a third drug, ipilimumab, to the standard two-drug combination (atezolizumab and bevacizumab) improves survival and tumor shrinkage in people with advanced liver cancer. About 229 patients will receive either the standard two drugs or all three. The goal is to see if the triple therapy works better for those who cannot have surgery or other local treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ipilimumab (added to atezolizumab and bevacizumab)
What this could lead to
If successful, this could offer a more effective first-line treatment option for advanced liver cancer, potentially extending survival.
What could go wrong
This is a phase II-III trial, so results are not yet conclusive. Adding ipilimumab may increase side effects without improving outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CAC Eugène Marquis
Rennes, France
-
CAC Gustave Roussy
Villejuif, France
-
CAC Paoli Calmettes
Marseille, France
-
CH HCC
Colmar, France
-
CH Saint-Jean
Perpignan, France
-
CHD Vendée
La Roche-sur-Yon, France
-
CHRU Hôpitaux de Tours
Tours, France
-
CHU
Angers, France
-
CHU Hôtel Dieu
Nantes, France
-
CHU Robert Debré
Reims, France
-
Cac Icans
Strasbourg, France
-
Centre Hospitalier
Cholet, France
-
Centre Hospitalier
Pau, France
-
Centre Hospitalier
Quimper, France
-
Centre Hospitalier
St-Malo, France
-
Centre Hospitalier
Valence, France
-
Ch Annecy Genevois
Pringy, France
-
Ch Duchenne
Boulogne-sur-Mer, France
-
Chu Amiens Picardie
Amiens, France
-
Chu Avicienne
Bobigny, France
-
Chu Beaujon
Clichy, France
-
Chu Brabois
Vandœuvre-lès-Nancy, France
-
Chu Charles Nicolle
Rouen, France
-
Chu Dupuytren
Limoges, France
-
Chu Estaing
Clermont-Ferrand, France
-
Chu Francois Mitterand
Dijon, France
-
Chu Haut Leveque
Pessac, France
-
Chu Haut-Leveque
Pessac, France
-
Chu L'Archet
Nice, France
-
Chu La Croix Rousse
Lyon, France
-
Chu La Miletrie
Poitiers, France
-
Chu La Pitie Salpetriere
Paris, France
-
Chu La Timone
Marseille, France
-
Chu Morvan
Brest, France
-
Chu Rangueil
Toulouse, France
-
Chu Saint Antoine
Paris, France
-
Chu Saint-Eloi
Montpellier, France
-
Chu Saint-Etienne
Saint-Priest-en-Jarez, France
-
Privé Bordeaux Nord
Bordeaux, France
-
Privé CONFLUENT
Nantes, France
-
Privé HPCA
Plérin, France
-
Privé LES BONNETTES
Arras, France
-
Privé Saint-Joseph
Marseille, France
-
Privé Saint-Joseph
Paris, France
-
Privé Sainte Anne
Strasbourg, France